ArticleThe Canadian journal of urology2025
Tranexamic acid and hematuria outcomes following aquablation for benign prostatic hyperplasia.
Article in The Canadian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aquablation/AquaBeam Waterjet Therapy for Benign Prostatic Hyperplasia: Three-Year Functional and Ejaculatory Outcomes in a Multicenter Real-World Italian Cohort.Lower urinary tract symptoms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAquablation is a robotic-assisted, water jet-based transurethral therapy for benign prostatic hyperplasia (BPH). Concerns about postoperative hematuria led to the practice of limited transurethral resection (TUR) with cauterization. This study aimed to assess the impact of tranexamic acid (TXA) on hematuria outcomes when combined with limited TUR after Aquablation.
methodsWe retrospectively analyzed men undergoing Aquablation at our institution (October 2020-July 2024). Demographic, prostate, surgical, and hematuria outcomes were extracted from electronic medical records. Kruskal-Wallis test compared medians.
resultsOf 131 patients, 113 (86%) had limited TUR; 31 (27%) received 1 g TXA perioperatively. TXA patients had larger prostates (86 g vs. 70 g, p = 0.003). No TUR patients, with or without TXA, required transfusion. Among TUR patients, TXA did not significantly affect preoperative, postoperative, or postoperative day-one hemoglobin. Patient-initiated communications and emergency visits for hematuria were minimal and similar between groups. Hematuria outcomes were independent of prostate size, TUR volume, or TUR-to-prostate ratio. Subgroup analysis (<80 g vs. ≥80 g) showed no TXA effect. No TXA recipient had a thromboembolic event within 30 days. At one month, median urinary flow increased by 12.8 mL/sec interquartile range [IQR]: 8.7-18.8, and median International Prostate Symptom Score (IPSS) decreased by 7 (IQR: 3-12).
conclusionsLimited TUR during Aquablation provides effective hemostasis. TXA had minimal impact on bleeding and was not associated with thromboembolic events. Routine TXA use should be reconsidered when limited TUR is performed.
Indexed as
Identifiers
41220359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.